Format

Send to

Choose Destination
In Vivo. 2019 Nov-Dec;33(6):2249-2254. doi: 10.21873/invivo.11730.

Combination Therapy With S-1, Oxaliplatin and Leucovorin in Patients With Advanced Esophageal Squamous Cell Carcinoma.

Author information

1
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
2
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan myamasaki@gesurg.med.osaka-u.ac.jp.
3
Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan.
4
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
#
Contributed equally

Abstract

BACKGROUND/AIM:

In this study, we assessed the safety and efficacy of combination therapy with S-1, oxaliplatin and leucovorin (SOL) in advanced esophageal squamous cell carcinoma (ESCC) patients.

PATIENTS AND METHODS:

Ten unresectable or recurrence ESCC patients, who had been previously treated with more than two regimens were included in this study. The treatment schedule comprised S-1 40-60 mg and fixed dose of leucovorin 25 mg together orally twice a day for one week, followed by one-week of rest. Oxaliplatin 85 mg/m2 was given as an intravenous infusion on day one, repeated every two weeks.

RESULTS:

Of the eight patients with measurable lesions, two patients with partial response (25%) and two with stable disease (25%) were observed. Disease control rate was 50%. Median progression-free survival and overall survival were 5.0 and 9.3 months, respectively. The main common adverse events were malaise (60%), decreased appetite (50%), peripheral sensory neuropathy (40%).

CONCLUSION:

SOL therapy showed promising antitumor activity with acceptable toxicity even for heavily pretreated ESCC.

KEYWORDS:

ESCC; Oxaliplatin; SOL

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center